$OTLC
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ร2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Healthcare
Sector
Biotechnology
Industry
Vuong Trieu
CEO
26
Employees
$0.04
Current Price
$39.83M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 7 | $37,832.25 | 850,759 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 7 | $37,832.25 | 850,759 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Trieu Vuong Director | Purchase | 240,000 | $0.04 | $10,344.00 | View Details |
| Jun 22, 2026 | Trieu Vuong Director | Purchase | 65,000 | $0.04 | $2,925.00 | View Details |
| Jun 24, 2026 | Trieu Vuong Director | Purchase | 115,000 | $0.04 | $5,175.00 | View Details |
| Jun 23, 2026 | Trieu Vuong Director | Purchase | 75,000 | $0.04 | $3,375.00 | View Details |
| Jun 22, 2026 | Shah Amit B. CFO | Purchase | 20,000 | $0.05 | $1,000.00 | View Details |
| Jun 15, 2026 | Trieu Vuong Director | Purchase | 96,000 | $0.04 | $4,320.00 | View Details |
| Jun 17, 2026 | Trieu Vuong Director | Purchase | 239,759 | $0.04 | $10,693.25 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.